… (PYs) of exposure. … of vedolizumab exposure (median exposure range, 1–1977 days). No
increased risk of any infection or serious infection was associated with vedolizumab exposure. …

… Higher, but statistically insignificant rates of enteric infections occurred in vedolizumab-exposed
patients (7.4/100 PYs; 95% CI: 6.6-8.3) compared to placebo (6.7 PYs; 95% CI: 3.2-10.1)…

… active Crohn's disease (CD) and ulcerative colitis (UC), based on clinical trials with exposure
… do not associate vedolizumab exposure during pregnancy with any new safety concerns. …

… ulcerative colitis [UC] or Crohn’s disease [CD]. The mechanism of action of vedolizumab
differs from that of other marketed biologics for the treatment of inflammatory bowel disease […

… Ulcerative colitis (UC) and Crohn's disease (CD) are chronic idiopathic inflammatory
bowel diseases (IBDs) for which no medical cure presently exists. Patients with moderate-to-severe …

… of the study was to evaluate vedolizumab exposure–response … vedolizumab therapy,
delineate vedolizumab exposure … relationship between vedolizumab exposure and response …

… However, in GEMINI LTS, vedolizumab was associated with lower rates of colon and rectal
… Although this analysis includes longer cumulative exposure to vedolizumab, the rate of …

… critical to achieving optimal treatment outcomes in inflammatory bowel diseases [Citation7]. …
This study characterized vedolizumab exposure−efficacy during the maintenance phase of …

… Several studies have reported the surgical outcomes of inflammatory bowel disease (IBD)
patients exposed to vedolizumab (VDZ) preoperatively, with conflicting results. This meta-…

… do not respond to vedolizumab treatment despite sufficient drug exposure in the blood … ,
we investigated vedolizumab tissue exposure and explored whether insufficient tissue exposure …